Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GLPG0187 prodrug · 1 trial · 1 indication
To characterize the amount of GLPG0187 in plasma over time - pharmacokinetics (PK) - after a single oral dose of either of 2 formulations of GLPG0187 prodrug in healthy subjects
| Arm | Type | Description |
|---|---|---|
| Period 1: formulation 1 oral solution | EXPERIMENTAL | - |
| Period 2: formulation 2 capsule | EXPERIMENTAL | - |
| Period 3: Selected formulation + food | EXPERIMENTAL | - |
| Period 4: Selected formulation at higher dose | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GLPG0187 prodrug | DRUG | - |
Inclusion Criteria: * Healthy male, age 18-50 years * BMI between 18-30 kg/m2 Exclusion Criteria: * Any condition that might interfere with the procedures or tests in this study * Drug or alcohol abuse * Smoking
GLPG0187 prodrug is an investigational small molecule developed by Lakefront Biotherapeutics. It was studied in a Phase 1 bioavailability trial in healthy volunteers. The compound is a prodrug form of GLPG0187, meaning it is designed to be converted in the body after administration. Its clinical development remains at the early Phase 1 stage.
GLPG0187 prodrug is being developed by Lakefront Biotherapeutics, which trades under the ticker LKFT. The company sponsored the Phase 1 bioavailability study of the compound. Lakefront Biotherapeutics is the developer associated with this asset.
GLPG0187 prodrug is in Phase 1 clinical development. It has completed one Phase 1 trial, a bioavailability study conducted in healthy volunteers in Belgium. No later-stage trials have been recorded, and the drug is not approved for any indication. It remains an investigational agent.
GLPG0187 prodrug has been studied in one completed Phase 1 trial, NCT01580644, titled Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers. The trial enrolled 12 male participants aged 18 years and older in Belgium. It was a controlled study with no randomization or blinding and has completed.
The Phase 1 trial NCT01580644 evaluated the bioavailability of GLPG0187 prodrug in healthy volunteers. It enrolled 12 male participants aged 18 years and older in Belgium. The study was controlled but not randomized and not double-blind. It has completed, and no active trials of GLPG0187 prodrug are ongoing.